Eric Ostertag, Poseida CEO (Poseida Therapeutics)
Novartis-backed Poseida is packing in the cash for its next-gen CAR-T work, adding a $110M venture raise on top of its newly-refiled IPO
A week after updating their S-1 in search of at least $115 million on the hot biotech IPO market, Poseida Therapeutics says it’s also raised a fresh venture round — a little more than a year after its last.
The first time around, after Poseida delayed its IPO during a government shutdown, the biotech reported a $150 million C round. This time around, it’s adding $110 million more from Fidelity Management Research Company and others.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters